MX344727B - Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas. - Google Patents

Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.

Info

Publication number
MX344727B
MX344727B MX2013005341A MX2013005341A MX344727B MX 344727 B MX344727 B MX 344727B MX 2013005341 A MX2013005341 A MX 2013005341A MX 2013005341 A MX2013005341 A MX 2013005341A MX 344727 B MX344727 B MX 344727B
Authority
MX
Mexico
Prior art keywords
tnfa antibody
high concentration
liquid formulations
improved high
antigen
Prior art date
Application number
MX2013005341A
Other languages
English (en)
Other versions
MX2013005341A (es
Inventor
Weber Carsten
Fraunhofer Wolfgang
Tschoepe Markus
Neu Michael
Redden Laura
Gastens Martin
Feick Alexander
K Paulson Susan
Zhu Tong
Original Assignee
Abbvie Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46051586&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX344727(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Biotechnology Ltd filed Critical Abbvie Biotechnology Ltd
Publication of MX2013005341A publication Critical patent/MX2013005341A/es
Publication of MX344727B publication Critical patent/MX344727B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una formulación farmacéutica líquida acuosa que comprende un anticuerpo anti-TNF-alfa, o una porción de unión al antígeno del mismo, el cual reduce el dolor asociado con la inyección en un sujeto, en al menos aproximadamente 50% cuando se compara con la inyección de una formulación de cualquier otra manera idéntica, que comprende al menos una sal y/o al menos un amortiguador. La invención también proporciona una formulación farmacéutica líquida acuosa que comprende un anticuerpo anti-TNF-alfa, o una porción de unión al antígeno del mismo, que tiene una mayor biodisponibilidad luego de la administración subcutánea en un sujeto. La formulación puede comprender una proteína terapéutica, tal como un anticuerpo anti-TNF-alfa, o una porción de unión al antígeno del mismo, o un biosimilar del mismo.
MX2013005341A 2010-11-11 2011-11-11 Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas. MX344727B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41272810P 2010-11-11 2010-11-11
US41396010P 2010-11-15 2010-11-15
PCT/US2011/060388 WO2012065072A2 (en) 2010-11-11 2011-11-11 IMPROVED HIGH CONCENTRATION ANTI-TNFα ANTIBODY LIQUID FORMULATIONS

Publications (2)

Publication Number Publication Date
MX2013005341A MX2013005341A (es) 2013-07-05
MX344727B true MX344727B (es) 2017-01-05

Family

ID=46051586

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005341A MX344727B (es) 2010-11-11 2011-11-11 Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.

Country Status (28)

Country Link
US (5) US8821865B2 (es)
EP (1) EP2637690B1 (es)
JP (3) JP5919606B2 (es)
KR (1) KR101841527B1 (es)
CN (2) CN105854016A (es)
AU (2) AU2011325974B2 (es)
BR (1) BR112013011699B1 (es)
CA (1) CA2815689C (es)
CY (1) CY1118373T1 (es)
DK (1) DK2637690T3 (es)
ES (1) ES2601202T3 (es)
HR (1) HRP20161753T1 (es)
HU (1) HUE029457T2 (es)
IL (1) IL226217A (es)
LT (1) LT2637690T (es)
ME (1) ME02506B (es)
MX (1) MX344727B (es)
NZ (1) NZ609469A (es)
PL (1) PL2637690T3 (es)
PT (1) PT2637690T (es)
RS (1) RS55385B1 (es)
RU (2) RU2015154965A (es)
SG (2) SG2014015069A (es)
SI (1) SI2637690T1 (es)
SM (1) SMT201600443B (es)
TW (2) TWI603739B (es)
WO (1) WO2012065072A2 (es)
ZA (1) ZA201406542B (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
NZ627177A (en) 2005-05-16 2016-02-26 Abbvie Biotechnology Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
AU2006259664A1 (en) * 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
US8182840B2 (en) 2005-09-27 2012-05-22 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
RU2529951C2 (ru) 2007-12-26 2014-10-10 Ксенкор, Инк. ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
EP2347247B1 (en) 2008-10-27 2019-06-26 Genalyte, Inc. Biosensors based on optical probing and sensing
BR112013011699B1 (pt) 2010-11-11 2019-04-24 Abbvie Biotechnology Ltd FORMULAÇÕES AQUOSAS LÍQUIDAS, SERINGA PRÉ-CHEIA OU DISPOSITIVO AUTOINJETOR E USO DAS DITAS FORMULAÇÕES PARA TRATAR UM DISTÚRBIO ASSOCIADO À ATIVIDADE DE TNFa COMPROMETIDA
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2012149486A1 (en) 2011-04-28 2012-11-01 Tissuetech, Inc. Methods of modulating bone remodeling
EP2717888B1 (en) 2011-06-10 2020-09-09 Tissuetech, Inc. Methods of processing fetal support tissues
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
WO2013186230A1 (en) * 2012-06-12 2013-12-19 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
WO2014011813A1 (en) * 2012-07-11 2014-01-16 Tissuetech, Inc. Compositions containing hc-ha/ptx3 complexes and methods of use thereof
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2883272A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
HRP20200434T1 (hr) 2012-09-07 2020-07-24 Coherus Biosciences, Inc. Stabilne vodene formulacije adalimumaba
CN104936607A (zh) * 2012-10-26 2015-09-23 鲁平有限公司 稳定的TNFR:Fc融合蛋白药物组合物
US9844594B2 (en) 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
CA2898262A1 (en) 2013-01-24 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Tnf-alpha antigen-binding proteins
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
KR20150129033A (ko) 2013-03-14 2015-11-18 애브비 인코포레이티드 저 산성 종 조성물 및 이의 제조 및 사용 방법
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
HK1213919A1 (zh) 2013-03-14 2016-07-15 Abbvie Inc. 低酸性物質組合物和利用置換色譜技術製備該組合物的方法
MX380569B (es) 2013-07-19 2025-03-12 Hexal Ag Métodos y formulaciones que permiten la modulación de respuestas inmunitarias relacionadas con la administración de un fármaco biofarmacéutico.
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
AU2014337263B2 (en) 2013-10-16 2019-12-12 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
IN2014MU01248A (es) * 2014-04-02 2015-10-09 Intas Pharmaceuticals Ltd
HUE029849T2 (en) 2014-05-23 2017-04-28 Ares Trading Sa Liquid pharmaceutical composition
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
EP3160996B1 (en) * 2014-06-30 2022-06-08 Merck Patent GmbH Anti-tnfa antibodies with ph-dependent antigen binding
WO2016056631A1 (ja) * 2014-10-08 2016-04-14 味の素株式会社 評価方法、評価装置、評価プログラム、評価システム、及び端末装置
TW201628649A (zh) * 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
TW201642914A (zh) 2015-02-23 2016-12-16 組織科技股份有限公司 用於治療眼部疾病及失調的裝置及方法
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
CN107847526A (zh) 2015-05-20 2018-03-27 组织技术公司 用于预防上皮细胞的增殖和上皮‑间充质转换的组合物和方法
CA2994043A1 (en) * 2015-07-31 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Antibody variants
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
CN109563161A (zh) * 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
US11020686B2 (en) 2016-08-16 2021-06-01 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
EP3529269B1 (en) 2016-10-19 2025-11-26 Invenra Inc. Antibody constructs
CN109982685B (zh) 2016-10-21 2022-03-11 美国安进公司 药物配制品及其制备方法
JP7102401B2 (ja) 2016-10-25 2022-07-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド クロマトグラフィーデータ解析のための方法およびシステム
MA47106A (fr) 2016-12-21 2019-10-30 Amgen Inc Formulations d'anticorps anti-tnf alpha
MX2019007019A (es) 2016-12-22 2019-08-16 Univ Degli Studi Magna Graecia Catanzaro Anticuerpo monoclonal dirigido a un epitope de cd43 sialoglicosilado especifico asociado al cancer.
CN108239150A (zh) 2016-12-24 2018-07-03 信达生物制药(苏州)有限公司 抗pcsk9抗体及其用途
RU2665966C2 (ru) * 2016-12-30 2018-09-05 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОα
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
RU2756619C2 (ru) * 2017-03-16 2021-10-04 ЭлДжи КЕМ, ЛТД. Жидкая композиция антитела против TNF альфа
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
KR102798879B1 (ko) 2017-09-19 2025-04-30 리제너론 파아마슈티컬스, 인크. 입자 형성을 감소시키는 방법 및 그것에 의해 형성된 조성물
JP2020534366A (ja) * 2017-09-20 2020-11-26 アルヴォテック エイチエフ アダリムマブ用医薬製剤
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
US20210231651A1 (en) * 2018-04-30 2021-07-29 Genalyte, Inc. Methods and compositions for point of care measurement of the bioavailability of therapeutic biologics
AU2019283314B2 (en) 2018-06-05 2024-11-07 GammaDelta Therapeutics Limited BTNL3/8 targeting constructs for delivery of payloads to the gastrointestinal system
EP3810268A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
TW202448568A (zh) 2018-07-02 2024-12-16 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
US20220041709A1 (en) * 2018-09-14 2022-02-10 Mitsubishi Tanabe Pharma Corporation Human anti-il-33 monoclonal antibody-containing pharmaceutical composition
PE20212185A1 (es) * 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
AU2020244106A1 (en) * 2019-03-18 2021-09-30 Alvotech Hf Aqueous formulations of TNF-alpha antibodies in high concentrations
CN114126587B (zh) * 2019-07-08 2023-11-28 株式会社Moresco 用于制备微型乳剂的组合物、微型乳剂、它们的制造方法、以及微型乳剂的应用
CN111420049A (zh) * 2019-08-22 2020-07-17 Biocad股份公司 抗-pd1抗体prolgolimab的水性药物组合物及其应用
JP6667043B1 (ja) * 2019-10-25 2020-03-18 株式会社Moresco マイクロエマルション、及びマイクロエマルションの利用

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5237054A (en) 1987-02-20 1993-08-17 Akzo Pharma Stabilized aqueous composition containing antibodies
DE10399036I1 (de) 1989-08-07 2004-04-01 Peptide Technology Ltd Bindeligande für Tumornekrosisfaktor.
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US20060246073A1 (en) 1991-03-18 2006-11-02 Knight David M Anti-TNF antibodies and peptides of human tumor necrosis factor
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6165467A (en) 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
ZA955642B (en) 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE122004000004I1 (de) 1996-02-09 2004-08-12 Abott Biotechnology Ltd Humane Antikörper welche an Humanen TNFalpha binden.
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
GB9705810D0 (en) 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2182202T5 (es) 1997-10-23 2007-12-01 Mitsubishi Pharma Corporation Preparacion de inmunoglobulinas para inyeccion intravenosa apta para ser almacenada a temperatura ambiente.
CA2371427A1 (en) 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Parenteral pharmaceutical composition containing humanized monoclonal antibody fragment and stabilizing method thereof
AU2228901A (en) 1999-12-28 2001-07-09 Chugai Seiyaku Kabushiki Kaisha Stable antibody compositions and injection preparations
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
JP4555436B2 (ja) * 2000-06-29 2010-09-29 富士通株式会社 薄膜樹脂基板への樹脂モールド方法及び高周波モジュール
JP5490972B2 (ja) * 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
DK1314437T3 (da) 2000-08-11 2014-07-14 Chugai Pharmaceutical Co Ltd Stabiliserede antistofindeholdende præparater
SE0003045D0 (sv) 2000-08-29 2000-08-29 Probi Ab New method
CA2423227C (en) 2000-10-12 2011-11-29 Genentech, Inc. Reduced-viscosity concentrated protein formulations
BR0206160A (pt) 2001-05-25 2004-10-26 Abbott Gmbh & Co Kg Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos
EP1391209A4 (en) 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATION
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
IL159048A0 (en) 2001-06-21 2004-05-12 Genentech Inc Sustained release formulation
US20030113316A1 (en) * 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
DE60229961D1 (de) 2001-08-29 2009-01-02 Chugai Pharmaceutical Co Ltd Antikörper enthaltende stabilisierte zubereitungen
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
JP5290489B2 (ja) 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
GB0202633D0 (en) 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
KR20110091822A (ko) 2002-02-14 2011-08-12 추가이 세이야쿠 가부시키가이샤 항체함유 용액제제
US20030161828A1 (en) 2002-02-19 2003-08-28 Abbott Gmbh & Co. Kg Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
SI1946776T1 (sl) 2002-02-27 2017-07-31 Immunex Corporation Stabiliziran tnfr-fc sestavek, ki obsega arginin
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040009172A1 (en) 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
JP2005530845A (ja) 2002-06-21 2005-10-13 アイデック ファーマシューティカルズ コーポレイション 抗体を濃縮するための緩衝化処方物およびその使用方法
US20090280065A1 (en) 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
TWI354561B (en) 2002-07-19 2011-12-21 Abbott Lab S A Pharmaceutical compositions and uses for treatment
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
WO2004055164A2 (en) 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
SI2236154T1 (en) 2003-02-10 2018-08-31 Biogen Ma Inc. THE FORM OF IMUNOGLOBULIN AND THE METHOD OF ITS PREPARATION
CN100563712C (zh) 2003-02-28 2009-12-02 阿雷斯贸易股份有限公司 肿瘤坏死因子结合蛋白的液体制剂
KR101235507B1 (ko) 2003-02-28 2013-02-20 추가이 세이야쿠 가부시키가이샤 단백질을 함유하는 안정화 제제
ZA200507757B (en) 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
WO2005033143A1 (ja) 2003-10-01 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 抗体の安定化方法及び安定化された溶液状抗体製剤
JPWO2005063291A1 (ja) 2003-12-25 2007-07-19 麒麟麦酒株式会社 抗体を含有する安定な水性医薬製剤
ES2297688T3 (es) 2004-03-12 2008-05-01 Intercell Ag Procedimiento para solubizar mezclas de peptidos.
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US7858082B2 (en) 2004-06-01 2010-12-28 Ares Trading S.A. Method of stabilizing proteins
US20060083741A1 (en) 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DOP2006000022A (es) 2005-01-28 2006-08-15 Wyeth Corp Formulaciones líquidas estabilizadas de polipetidos
TWI398272B (zh) 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
NZ627177A (en) 2005-05-16 2016-02-26 Abbvie Biotechnology Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
US8858935B2 (en) 2005-05-19 2014-10-14 Amgen Inc. Compositions and methods for increasing the stability of antibodies
AU2006259664A1 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
ATE501248T1 (de) 2005-07-02 2011-03-15 Arecor Ltd Stabile wässrige systeme mit proteinen
US20070190047A1 (en) 2005-07-29 2007-08-16 Amgen, Inc. Formulations that inhibit protein aggregation
NZ599176A (en) 2005-08-03 2014-04-30 Immunogen Inc Immunoconjugate formulations
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
RS53055B (sr) 2005-11-01 2014-04-30 Abbvie Biotechnology Ltd Postupci za određivanje efikasnosti adalimumaba kod ispitanika koji imaju ankilozirajući spondilitis koristeći ctx-ii i mmp3 kao biomarkere
EP1962907A2 (en) 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
KR20080098504A (ko) 2006-02-03 2008-11-10 메디뮨 엘엘씨 단백질 제제
RS52459B (sr) 2006-02-07 2013-02-28 Shire Human Genetic Therapies Inc. Stabilizovane kompozicije glukocerebrozidaze
NZ571479A (en) 2006-04-05 2012-10-26 Abbott Biotech Ltd Antibody purification
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20090317399A1 (en) 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
WO2007120656A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
US20080118496A1 (en) 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
WO2007120626A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of ankylosing spondylitis
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
JP2009534390A (ja) 2006-04-21 2009-09-24 アムジェン インコーポレイテッド 生物医薬品製剤のための緩衝剤
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
US20080311043A1 (en) 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
US7571225B2 (en) 2006-06-29 2009-08-04 Stratavia Corporation Standard operating procedure automation in database administration
KR101396797B1 (ko) 2006-06-30 2014-05-26 애브비 바이오테크놀로지 리미티드 자동 주사 장치
MX345141B (es) 2006-09-13 2017-01-18 Abbvie Inc * Mejoras de cultivos celulares.
CA2663892A1 (en) 2006-09-25 2008-04-03 Medimmune, Llc Stabilized antibody formulations and uses thereof
JP5631591B2 (ja) 2006-10-06 2014-11-26 アムジエン・インコーポレーテツド 安定な抗体製剤
EP2094247B1 (en) 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
RU2486296C2 (ru) 2006-10-27 2013-06-27 Эбботт Байотекнолоджи Лтд. КРИСТАЛЛИЧЕСКИЕ АНТИТЕЛА ПРОТИВ hTNFα
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
JP2010519223A (ja) 2007-02-16 2010-06-03 ワイス エルエルシー ソルビトールを含むタンパク質処方物
KR101578561B1 (ko) 2007-04-26 2015-12-17 바이엘 헬스케어 엘엘씨 냉동 저장을 위한, 재조합 단백질의 액상 용액의 안정화
EP2144629A1 (en) 2007-05-02 2010-01-20 F. Hoffmann-Roche AG Method for stabilizing a protein
US8092998B2 (en) 2007-05-31 2012-01-10 Abbott Laboratories Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders
EP2152318A4 (en) 2007-06-01 2011-12-07 Abbott Biotech Ltd COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
JP2010530846A (ja) 2007-06-01 2010-09-16 アコロジックス インコーポレイティッド 高温で安定なペプチド製剤
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
US20110014676A1 (en) 2007-06-29 2011-01-20 Battelle Memorial Institute Protein stabilization
EP2173380A4 (en) 2007-07-13 2011-08-31 Abbott Biotech Ltd METHOD AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa HEMMER
CA2697163A1 (en) 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
WO2009032128A1 (en) 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
NZ622583A (en) * 2007-11-30 2015-08-28 Abbvie Biotechnology Ltd Protein formulations and methods of making same
CN101965514A (zh) 2008-01-03 2011-02-02 艾博特生物技术有限公司 预测化合物在治疗银屑病中的长期功效
MX2010007729A (es) 2008-01-15 2010-08-04 Abbott Lab Vectores de expresion de mamifero mejorados y uso de los mismos.
CA2711984A1 (en) 2008-01-15 2009-07-23 Abbott Gmbh & Co. Kg Powdered protein compositions and methods of making same
WO2009118662A2 (en) 2008-03-24 2009-10-01 Abbott Biotechnology Ltd. Methods and compositions for treating bone loss
EP2424594A4 (en) 2009-04-29 2014-12-24 Abbvie Biotechnology Ltd AUTOMATIC INJECTION DEVICE
RU2560701C2 (ru) * 2009-05-04 2015-08-20 Эббви Байотекнолоджи Лтд. Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа
MX2012008985A (es) 2010-02-02 2012-09-07 Abbott Biotech Ltd Metodos y composiciones para predecir la capacidad de respuesta al tratamiento con el inhibidor de tnf-alfa.
US8747854B2 (en) 2010-06-03 2014-06-10 Abbvie Biotechnology Ltd. Methods of treating moderate to severe hidradenitis suppurativa with anti-TNF-alpha antibodies
BR112013011699B1 (pt) 2010-11-11 2019-04-24 Abbvie Biotechnology Ltd FORMULAÇÕES AQUOSAS LÍQUIDAS, SERINGA PRÉ-CHEIA OU DISPOSITIVO AUTOINJETOR E USO DAS DITAS FORMULAÇÕES PARA TRATAR UM DISTÚRBIO ASSOCIADO À ATIVIDADE DE TNFa COMPROMETIDA

Also Published As

Publication number Publication date
US20120263731A1 (en) 2012-10-18
HRP20161753T1 (hr) 2017-02-10
JP5919606B2 (ja) 2016-05-18
CY1118373T1 (el) 2017-06-28
SMT201600443B (it) 2017-01-10
US20160017030A1 (en) 2016-01-21
TW201641119A (zh) 2016-12-01
HUE029457T2 (en) 2017-02-28
RU2639386C2 (ru) 2017-12-21
AU2011325974B2 (en) 2016-10-27
ES2601202T3 (es) 2017-02-14
AU2011325974A1 (en) 2013-05-09
CA2815689A1 (en) 2012-05-18
PT2637690T (pt) 2016-12-27
CN105854016A (zh) 2016-08-17
IL226217A (en) 2017-08-31
WO2012065072A2 (en) 2012-05-18
BR112013011699B1 (pt) 2019-04-24
MX2013005341A (es) 2013-07-05
AU2016202136A1 (en) 2016-04-28
SG2014015069A (en) 2014-07-30
JP2013543868A (ja) 2013-12-09
US20190211093A1 (en) 2019-07-11
US20140377275A1 (en) 2014-12-25
EP2637690B1 (en) 2016-09-21
JP2016172740A (ja) 2016-09-29
CA2815689C (en) 2016-11-22
TWI606840B (zh) 2017-12-01
HK1189162A1 (zh) 2014-05-30
RU2013126655A (ru) 2014-12-20
US8821865B2 (en) 2014-09-02
LT2637690T (lt) 2016-10-25
JP6062582B2 (ja) 2017-01-18
KR20130135266A (ko) 2013-12-10
RS55385B1 (sr) 2017-03-31
NZ609469A (en) 2015-02-27
RU2015154965A (ru) 2019-01-16
US20220010005A1 (en) 2022-01-13
EP2637690A4 (en) 2014-04-30
BR112013011699A2 (pt) 2015-09-29
PL2637690T3 (pl) 2017-03-31
TWI603739B (zh) 2017-11-01
WO2012065072A3 (en) 2012-07-26
SI2637690T1 (sl) 2016-11-30
CN103458926A (zh) 2013-12-18
JP2016128466A (ja) 2016-07-14
CN103458926B (zh) 2016-10-26
TW201244736A (en) 2012-11-16
IL226217A0 (en) 2013-07-31
DK2637690T3 (da) 2017-01-02
SG190069A1 (en) 2013-06-28
ME02506B (me) 2017-02-20
ZA201406542B (en) 2015-09-30
KR101841527B1 (ko) 2018-03-23
EP2637690A2 (en) 2013-09-18

Similar Documents

Publication Publication Date Title
MX344727B (es) Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
MX2011011772A (es) Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina.
MX2016002152A (es) Metodo para aumentar la expresion de proteinas codificadas por arn.
MY188825A (en) High-concentration monoclonal antibody formulations
SG10201806539XA (en) Liquid protein formulations containing ionic liquids
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
MX2023008626A (es) Proteinas klotho recombinantes terapeuticas y composiciones y metodos que involucran a las mismas.
HK1208629A1 (en) Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency
IL224048B (en) Antiganic composition comprising whole killed or attenuated pathogenic eschrichia coli ( e.coli) cells for intradermal or subcutaneous administration for treating a human patient for crohn's disease
EA201492292A1 (ru) Препарат антител
WO2011109365A3 (en) Concentrated protein formulations and uses thereof
MX2019006633A (es) Formulaciones de anticuerpo.
AU2016204185A1 (en) Methods of administering beta7 integrin antagonists
HRP20171931T1 (hr) Farmaceutska formulacija koja obuhvaća biofarmaceutski lijek
EP4534107A3 (en) Protein complex by use of a specific site of an immunoglobulin fragment for linkage
RU2016105462A (ru) Способы и композиции, которые обеспечивают модуляцию иммунных ответов, связанных с введением биофармацевтического лекарственного средства
HRP20191137T1 (hr) Formulacije otopina konstruiranih anti-il-23p19 antitijela
NZ702342A (en) Pharmaceutical formulation
EA201491513A1 (ru) Рекомбинантные штаммы escherichia coli
EA201790223A1 (ru) Водный препарат, содержащий парацетамол и ибупрофен
SE0301663D0 (sv) Analysmetod för infusionsläkemedel
BR112018008769A2 (pt) formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída
MX383557B (es) Formulaciones inyectables de paracetamol.
HK1226323A1 (en) Liquid protein formulations containing ionic liquids
HK1226310A1 (en) Liquid protein formulations containing water soluble organic dyes

Legal Events

Date Code Title Description
FG Grant or registration
GD Licence granted